The abbreviations used are: TR2, human testicular orphan receptor-2; TR4, human testicular orphan receptor-4; HRE, hormone receptor response element; DR, direct repeat; HPV-16, human papillomavirus type 16; LCR, long control region; CAT, chloramphenicol acetyltransferase; DBD, DNA binding domain; CHO, chinese hamster ovary; TK, thymidine kinase. 
INTRODUCTION
Orphan receptors, or receptors without known ligands, make up the vast majority of members of the steroid receptor superfamily (1) (2) (3) . Members of this family are characterized by a highly conserved DNA-binding domain (DBD) and a carboxy-terminal ligand-binding domain.
The conserved amino acid sequence within the DBDs of these receptors is predicted to form two zinc finger motifs (1) . Additionally, steroid receptors bind to specific DNA sequences known as hormone response elements (HREs), through which regulation of target gene expression may occur (1) . The cDNA of the human TR2 orphan receptor (TR2) was isolated from the screening of human testis and prostate cDNA libraries for the androgen receptor. In the screening, an oligonucleotide probe homologous to the highly conserved DBD of the glucocorticoid receptor was used (2) . Four TR2 cDNA clones (TR2-5,-7,-9,-11) were isolated, and found to share identical sequences in the N-terminal and DBD regions, yet differ in the length of the C-terminal putative ligand binding domain (3) .
Through further study of TR2, it was found that this orphan receptor binds to a consensus HRE composed of a direct repeat (DR) with variable spacing (AGGTCAX (n) AGGTCA, n=0-6) (4). Using the known TR2 HRE sequence as a guide, it was determined that TR2 has modulatory effects on several signaling pathways, such as those involving retinoic acid (4), thyroid hormone (5) , and ciliary neurotrophic factor (6) . Moreover, expression of the erythropoietin gene (7), aldolase gene (8) , histamine H1 receptor (9) , and Simian Virus 40 (SV40) (10) is also regulated by TR2. To add to the list of TR2 responsive genes, we have found a TR2 DR4 consensus site 4 increased risk for the development of cervical neoplasia, one of the most common cancers in women throughout the world. HPV is thought to contribute to the development of 10-15% of all human cancers (11) . Papillomaviruses are epitheliotropic organisms, and therefore result in chronic infection of the skin and mucous membranes. The most common site of infection of genital HPVs in women is the stratified squamous epithelium at the squamocolumnar junction of the cervix. Over 70 HPV types have been identified, and each is classified as either low risk (eg.
HPV-6, HPV-11) based on association with benign lesions, or high risk (eg. HPV-16, HPV-18) based on association with cervical carcinoma. Over 90% of cervical cancers show high risk HPV infection, and over 20% of genital HPV types are associated with cervical cancer; high risk HPV-16 is the predominant tumor-associated type (12) .
A common element in pathways involving either TR2 or HPV is the p53 tumor suppressor. The p53 protein is a transcription factor that binds to a specific regulatory sequence and modulates the expression of various target genes such as p21 waf1/cip1 , bax, mdm2 and cyclin G (reviewed in 11). Through regulation of its target genes, p53 is able to suppress cell cycle progression in response to DNA damage. As a tumor suppressor, p53 is able to block DNA replication after damage has occurred, allowing time for damage repair or the induction of the onset of apoptosis (13, 14) . This process prevents mutations, induced via DNA-damaging agents, from being replicated and passed on, thus reducing the potential for cellular transformation. p53 expression has been shown to increase after insults such as gamma-irradiation or actinomycin D treatments, which damage DNA directly. Along with p53 induction, cells demonstrate corresponding cell cycle arrest in phase G 1 (15) . Relating this to TR2, it has been shown that ionizing radiation represses the expression of the orphan receptor at both transcriptional and translational levels, and that this repression is mediated by p53 (16). The TR2 protein expression kinetics in cells after irradiation was opposite that of p53 expression; TR2 levels decreased by guest on October 1, 2017 http://www.jbc.org/ Downloaded from dramatically 1-2h after treatment and were restored to pre-treatment levels over time, whereas p53 levels increased soon after treatment and decreased over time. The suggestion that p53 plays a role in the repression of TR2, which is induced by ionizing radiation, was further substantiated by the reduction in TR2 expression after p53 levels were increased in the absence of irradiation, as well as by the lack of TR2 repression when a mutant form of p53 was overexpressed (16).
Having established a functional relationship between TR2 and p53, further study will be necessary to characterize the mechanism responsible for this phenomenon.
It is known that steroid hormone response elements exist within the HPV-16 viral regulatory region. Both progesterone and glucocorticoid have been shown to induce HPV-16 gene expression through receptor association with three glucocorticoid response elements (GREs) within the HPV-16 LCR (17-20). We now report that TR2 is also able to modulate the expression of HPV-16 genes, and that it does so through binding to a TR2 response element located in the HPV-16 LCR. We also demonstrate that E6 is able to reduce the repression of TR2 by p53, which is likely to occur through the binding of p53 by E6, an event that initiates p53 degradation. Cumulatively, our data demonstrate a positive-feedback regulatory pathway between TR2 and HPV-16, providing evidence for a novel relationship between a steroid receptor and the HPV-16 DNA tumor virus.
MATERIALS AND METHODS
Immunohistochemical Staining  Three 8-10 week old female ICR mice (Taconic, Germantown, NY) were sacrificed, and the vagina, uterus, and cervix of each animal were removed. The tissue was fixed in Histochoice MB (Amresco, Solon, Ohio) at 4°C overnight, and embedded in paraffin. Saggital sections through each of the three anatomic regions of interest were cut at a thickness of 7µm, dried at 37°C overnight, and processed for modified hemotoxylin/eosin (21) and immunohistochemical staining. For immunohistochemical staining, sections were stained with the mouse monoclonal, anti-TR2 antibody G204, and a biotinylated anti-mouse secondary antibody (Vector Laboratories, Burlingame, CA). Staining was visualized upon development with the DAB substrate kit (Vector Laboratories, Burlingame, CA). Stained sections were analyzed via light microscopy (Nikon, Tokyo, Japan) and photographed.
Plasmids  The TR2pCAT reporter plasmid consists of the 2.7 kb 5'-flanking region of the TR2 orphan receptor (22) linked to the CAT gene. pC53-SN3 (gift from B. Vogelstein, described in 23) was constructed by inserting wild-type p53 cDNA into the pCMV-Neo-Bam vector. p1321 and p1434 (gifts from P. M. Howley , described in 24) contain the E6 and E7 genes of HPV-16, driven by the human β-actin promoter. p1321 expresses both E6 and E7 genes, whereas p1434 contains a translation termination linker within E6. The plasmid pSG5-hTR2-11 (25) expresses full-length TR2, and the plasmid pCMX-TR4 (gift from R. M. Evans, described in 7 employing a method similar to that used to create the chimeric pSG5-AR-TR2-AR plasmid (25) .
Site-directed mutagenesis (25) Twenty-four hours after transfection, the medium was changed. After another 24 hours, cells were subjected to freeze-thaw lysis in 250 mM Tris-HCl (pH 7.8), and the resulting cell extracts were assayed for chloramphenicol acetyltransferase (CAT) activity. CAT activity was assessed via Phosphorimager scanning and quantitated using ImageQuant software (Molecular Dynamics Inc., Sunnyvale, CA).
In Vitro Transcription/Translation  The expression vector pSG5-hTR2-11 was utilized to produce in vitro transcribed and translated TR2 protein in the TNT coupled rabbit reticulocyte lysate system (Promega, Madison, WI).
Electophoretic Mobility Shift Assay (EMSA)  EMSA analysis was performed as described previously (7). Briefly, the HPV-16 DR4RE oligonucleotide was end-labeled with 32 P to serve as a probe to demonstrate the binding of in vitro expressed TR2 to the DR4 sequence within the LCR of HPV-16. For competition reactions, unlabeled HPV-16 DR4RE oligonucleotides were mixed with labeled probe prior to its addition to the reaction. HeLa cell nuclear extract was prepared as described previously (47) . Antibody shift analysis involved the addition of 1 µl of the monoclonal anti-TR2 orphan receptor antibody, G204, to the reaction for 15 min., at room temperature, prior to gel loading.
RESULTS

TR2 protein is expressed in cell types commonly infected by HPV-16  To establish
physiological relevance for studying the interaction of regulatory pathways involving TR2 and HPV-16, staining of mouse vaginal and cervical tissue, with a monoclonal antibody specific to TR2 (G204), was performed. As HPV-16 is epitheliotropic, and the genital form commonly infects the stratified squamous epithelial layers of the uterine cervix and vagina (12), we sought to determine whether TR2 was expressed in the same cell types within these regions. The anti-TR2 monoclonal antibody G204 was used in immunohistochemical staining of longitudinal sections of paraffinembedded mouse cervix and vagina samples. After staining, it was clear that TR2 was present in the nuclei of stratified squamous epithelial cells within the regions known to be susceptible to HPV-16 infection (Fig. 1) . These results supported our interest in further characterizing the potential regulatory relationship between TR2 and HPV-16.
HPV-16 oncogene E6 antagonizes p53-mediated repression of TR2 gene expression-
In an earlier study (16), we demonstrated that TR2 levels in MCF-7 cells were repressed by ionizing radiation, and that the kinetics of the down regulation of TR2 correlated with a concurrent increase in p53 expression. Additionally, it was shown that upon co-transfection of the SV40 large T antigen, a viral oncoprotein known to associate with, and inactivate p53 (37-40), TR2 reporter expression was not repressed after exposure of cells to ionizing radiation. Further, using expression plasmids expressing either wildtype or mutant forms of p53, it was found that wildtype p53 was able to mediate suppression of TR2 expression. The mutant form of p53 was unable to affect expression of TR2. Having demonstrated repression of TR2 mediated by the p53 tumor suppressor (16), and recognizing that HPV-16 E6 binds and promotes degradation of p53 (30-31), we sought to determine whether the suppressive effect of p53 on TR2 expression could be attenuated by E6.
Using the lung-derived, p53-null H1299 cell line, the effect of increasing levels of a plasmid expressing both the HPV-16 E6 and E7 proteins on TR2 promoter activity was tested (Fig. 2) . To demonstrate the suppressive effect of p53 on TR2-reporter gene (TR2pCAT) (22) (32), it is unlikely that the 52 amino acid, truncated form of E6, expressed from plasmid p1434 (24) , is able to bind p53. It has also been shown that the ability of E6 to bind p53 is necessary for p53 degradation (32), which may explain the loss of the attenuating effect of truncated E6 on p53-mediated suppression of TR2-promoter expression. 
Identification of a direct repeat 4 response element in the HPV-16 LCR-Sequence
Induction of HPV-16 LCR-directed gene expression by TR2-Having determined that E6 is
able to affect TR2 expression (Fig. 2) , presumably through induction of p53 degradation, and after discovering a TR2 response element within the HPV-16 LCR (Fig. 3 ), we were interested in testing whether TR2 could regulate the expression of the E6 oncogene. An expression vector containing the region which controls E6 gene expression (pGL2-LCR, containing the HPV-16 LCR) (27) was linked to a CAT reporter (HPV-16 LCR-CAT), and then co-transfected with a vector constructed to express TR2 (pSG5-hTR2-11) (25), in the Chinese hamster ovary (CHO) cell line. As shown in Fig. 4 , the HPV-16-LCR-driven CAT expression was significantly induced by TR2 in a dosedependent manner (lanes 1-5) . A similar induction of HPV-16 LCR-CAT activity also occurred when we replaced the TR2-expressing plasmid with that which expresses the highly homologous TR4 orphan receptor (Fig. 4, lanes 10-13) (33). Both TR2 and TR4 recognize the same consensus HRE sequence and are able to modulate some of the same target genes (6-7, 26, 41) . Therefore, it is not surprising that both TR2 and TR4 are able to induce HPV-16 LCR-CAT activity. In contrast, when we replaced pSG5-hTR2-11 with pSG5-TR2-AR-TR2 (2A2) (25) , which expresses a chimeric receptor in which the DBD of the androgen receptor is substituted for the TR2-DBD, the induction of HPV-16 LCR-CAT was lost (Fig. 4, lanes 6-9) . This loss of reporter induction suggests that the DBD of TR2 is essential for recognition of the HRE located within the HPV-16
LCR.
Functional analysis of the HPV-16 DR4RE-To determine whether the identified HPV-16
DR4RE is necessary for the regulatory effect of TR2 on E6 expression, we used a site-directed PCR mutagenesis strategy (25) to create a mutant of HPV-16 LCR-CAT. The mutant has an internal deletion of 27 bp, including the HPV-16 DR4RE, the sequence recognized by TR2 ( Fig. 5A and 5B). The mutant (HPV-16 LCR-D27CAT) was co-transfected with expression vectors that contain either TR2 or TR4 (25) (26) , into CHO cells. In contrast to HPV-16 LCR-CAT, which can be significantly induced by TR2 or TR4 (Fig. 4 and Fig. 5C lanes 6-8) , the CAT activity of HPV-16-LCR-D27CAT showed no significant increase with transfection of TR2 or TR4 (Fig. 5C , lanes 9-11) expression plasmids. Furthermore, neither TR2 nor TR4 were successful in modulating expression of a promoter/reporter gene that does not contain a response element recognized by these receptors (AR2.3CAT) (Fig 5C, lanes 1-5) . These data demonstrate that the HPV-DR4RE, located 175bp upstream of the TATA-box at bp 65 in the E6 ORF, is necessary for TR2-mediated induction of HPV-16 gene expression, and that TR2 and TR4 are not general regulators of transcription, but bind to specific sequences within particular target genes.
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( Fig. 3) was inserted into the -32TK-CAT vector, in either sense or antisense orientation (Fig. 6A) .
H1299 cells were then transfected with either parental vector, sense HPV-DR4RE (+)TK-CAT or
antisense HPV-DR4RE(-)TK-CAT, along with increasing amounts of TR2 or TR4. Our data exhibit no effect on vector (Fig. 6B, lanes 1-3) , induction of reporter activity by both TR2 (Fig. 6B , lanes 4-6 and 10-12) and TR4 (Fig. 6B, lanes 7-9 and 13-15 ) in a dose-dependent manner, regardless of orientation. These data suggest that the HPV-16 DR4RE alone is sufficient to allow The second molecular pathway that exists in the feedback loop involving TR2, HPV-16 and p53 is that linking TR2 with HPV-16. In a study examining the effect of both p53 and the retinoblastoma (Rb) protein on TR2, in the context of cryptorchidism, it was found that each tumor suppressor protein (p53 or Rb) had a repressive effect on TR2 expression (42) . The known binding of proteins E6 and E7 to p53 and Rb, respectively, as well as the subsequent ubiquitin-mediated degradation of the tumor suppressor proteins known to result from such binding (30, (43) (44) (45) further implicated p53 and Rb as mediators of TR2 repression (42) . The model proposed in the cryptorchidism study suggests that the down-regulation of TR2 by p53 involves a pathway in which p53 upregulates one of its targets, p21. As Rb can be regulated via phosphorylation by cyclin dependent kinase (CDK), and loses its ability to block cell-cycle progression when hyperphosphorylated, the CDK-inhibitor, p21, prevents the inactivation of Rb. Rb is then able to bind transcription factor E2F, and reduce expression of TR2 (42) . Although the possibility exists that alternative pathways may be present which result in p53-mediated regulation of TR2, the above described p53 à p21 à CDK à Rb à E2F à TR2 pathway may also occur in the context of HPV-16 infection and proliferation. Given the binding and degradation of p53 and Rb which occurs in the presence of the HPV-16 E6 and E7 proteins, it follows that upon HPV-16 infection and early gene expression less p53 protein would be present to induce p21 and inhibit CDK activity.
Therefore, less active Rb would be present to bind E2F. Furthermore, the binding of Rb by E7
would directly inhibit the sequestration of E2F meditated by Rb-E2F binding. In both cases TR2 suppression would be attenuated, and TR2 would be free to bind its response element in the LCR of HPV-16, thus upregulating viral gene expression. (16), we hypothesize that there is a positive feedback regulatory mechanism involving TR2, HPV-16, and p53 (Fig. 7) . In a more general sense, to depict the involvement of HPV-16 in the context of papilloma virus infection, we suggest that TR2 induces HPV-16 E6, and E6, in turn, reduces the available p53. In this way, p53-mediated cell cycle regulation, as well as TR2 repression, is attenuated. As a result, more TR2 will be available to continue to upregulate E6
expression. As the cell cycle continues, more and more cells will undergo HPV infection, and loss analysis was performed using in vitro expressed TR2 protein and 32 P-labeled HPV-16-DR4RE.
Binding reaction mixture containing the isotope-labeled probe was incubated with increasing amounts of TR2 alone (lanes 2 and 3) , or in the presence of either excess unlabeled oligonucleotide (50X) (lane 4), or a non-specific DNA competitor (SP1, lane 3). Lane 1 contains the 32 P-labeled probe alone. In lanes 6 and 7, endogenous TR2 from HeLa cell nuclear extract is shown to bind 32 P-labeled HPV-16 DR4RE, and in lane 7, addition of a monoclonal anti-TR2
antibody further demonstrates the specificity of TR2 in the formation of the observed complex.
The slower migrating, 32 P-labeled HPV-16 DR4RE/TR2/anti-TR2 antibody complex is indicated by the unlabeled arrow. -11) , as the receptor binding site (DR4RE) is no longer present in the mutant construct. Additionally, a non-TR2, or -TR4 regulated reporter, AR2.3CAT, was cotransfected with either TR2 or TR4. The lack of regulation of the AR2.3CAT
reporter by TR2 or TR4 demonstrates the specificity of these orphan receptors for particular binding sequences, and proves that they are not functioning as general regulators of transcription.
CAT activities were represented as induction fold in comparison to the activity of the HPV-LCR-CAT reporter alone (lanes 6 and 9, set at 1-fold). 
